Skip to main content

Curis Inc(CRIS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Curis Provides Third Quarter 2022 Business Update

PR Newswire - Wed Nov 9, 2022

Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022

Curis focuses its resources to drive the development of emavusertib

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza